echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Why is the supplementary medicine "chopping board fish meat"?

    Why is the supplementary medicine "chopping board fish meat"?

    • Last Update: 2019-06-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In the late 1930s, in the Northern Shaanxi plateau, the rear of the Communist Party of China, antibiotics were blocked by the enemy, and the Anti Japanese base area used Chaihu Decoction to control the infection of soldiers after injury In 1940, Chaihu water was distilled and made into injection Its good antipyretic and antiphlogistic effect greatly reduced the death rate of wounded soldiers Meanwhile, it was found that it also had remarkable effect in the treatment of cold, recurrent fever, puerperal fever, antipyretic during the development period of tuberculosis, antimalarial and other aspects, alleviating the urgent need for medicine in the root areas Later, this kind of traditional Chinese medicine injection became the synonym of auxiliary medicine This situation continued until the 1960s and 1970s, and until the 1980s, there were more than 1400 kinds of traditional Chinese medicine injections that were lack of supervision In the 1990s, with the "east wind" of new drug approval, many new traditional Chinese medicine injections were approved for listing or received help There are many people who rely on bribes for convenience, including step pharmaceutical, which is deeply involved in the storm of public opinion According to the national ADR monitoring annual report (2017), the number of ADR / event reports of traditional Chinese medicine in 2017 was slightly lower than that in 2016 In 2017, the distribution of drug delivery routes involved in ADR / event reports, injection accounted for 64.7% of the overall report, 77.6% of the serious reports, 54% of them were intravenous injection, and 0.6% of them were other injection Therefore, since last year, the National Drug Administration (nmpa) has publicized on its official website more and more times to require the modification of instructions for traditional Chinese medicine injections On July 3 last year, the State Food and Drug Administration decided to add warning words to Qingkailing Injection (including Qingkailing injection, Qingkailing for injection (freeze-dried)) and Yiqifumai (freeze-dried) instructions, and revise adverse reactions, taboos and precautions Among them, the above three products are large varieties of traditional Chinese medicine injections with sales of over 100 million, involving three listed companies Shenwei Pharmaceutical Co., Ltd is the largest manufacturer of Qingkailing Injection Market share in China Yiqi Fumai (freeze-drying) for injection is the exclusive product of Tianshili company, while Qingkailing (freeze-drying) for injection is the exclusive product of Guizhou Yibai Since the beginning of this year, nmpa has been on the rise again As of June of this year, nmpa has issued three announcements on the modification instructions of traditional Chinese medicine injections, including Chansu injection, Tongguanteng injection and Zhongjiefeng injection It can be said that the auxiliary drugs represented by traditional Chinese medicine injections have entered the period of depression rectification Improper or even wrong abuse of auxiliary drugs has also squeezed precious medical insurance funds, which unfairly increases the total burden on the whole society to the people This year, the state is about to issue a new version of the medical insurance catalog It can be expected that this situation will also be directly reflected in the new version of the medical insurance catalog It is believed that the new version of the medical insurance catalog will eliminate a large number of auxiliary drugs with little clinical value and leave valuable medical insurance funds to the truly valuable and effective varieties In fact, the decline of enterprise performance, the auxiliary drug represented by traditional Chinese medicine injection has been one of the symbols of the modernization of traditional Chinese medicine for many years, and the policy makers are hesitant for many times about how to develop in the future, and this attitude also affects the instability of enterprise development direction to a certain extent This kind of instability is most intuitively reflected in the company's performance For the large-scale manufacturers of auxiliary drugs, although it's hot June, they still feel extremely cold and long At present, the large-scale manufacturers of traditional Chinese medicine injections listed on the A-share market have seen a significant decline in their performance For example, Dali pharmaceutical industry achieved an operating income of 401 million last year, a year-on-year increase of 47.2%, but its net profit has declined by 75.9%, Only 10.7 million yuan, the deduction of non net profit is 93%, only 2.32 million yuan In the first quarter of this year, not only net profit and non net profit of deduction continued to decline, but also operating revenue rarely fell by 25% Dali pharmaceutical explained that the poor performance in 2018 was mainly due to the obvious decline in sales volume due to the impact of medical insurance cost control measures and drug restriction policies; in order to timely digest the inventory, the company reduced its production plan, resulting in large-scale production reduction and shutdown losses According to last year's annual report, the main products of Dali pharmaceutical are "Zhongjing brand" Xingnaojing injection and Shenmai injection, both of which are traditional Chinese medicine injection In 2018, the revenue of traditional Chinese medicine products reached 401 million, accounting for 89% Dali Pharmaceutical Co., Ltd is not the only one whose performance has declined For a while ago, Steph Pharmaceutical Co., Ltd was questioned by Shanghai stock exchange because of its sales expenses On the evening of May 12, Steph pharmaceutical announced that it received the post audit inquiry letter from Shanghai Stock Exchange on the company's 2018 annual report, which focused on the production and sales volume, revenue, gross profit margin, curative effect of the company's core products, such as traditional Chinese medicine injection, etc Whether there are adverse reactions or quality problems reported by the media As the core and exclusive product of step pharmaceutical, the total sales from 2013 to 2015 was 11.352 billion, accounting for more than 30% of the revenue and more than 40% of the profit But behind the high profit and high growth is the frequent occurrence of adverse reactions and increasingly strict restrictions on use In the 2017 national medical insurance catalog, Danhong injection is listed in the class B list of medical insurance, which is strictly restricted to the severe patients with clear evidence of acute attack of ischemic cardio cerebrovascular disease in secondary and above medical institutions At the same time, due to frequent serious adverse reactions, Danhong injection was included in the key monitoring for 26 times According to the data of minenet, the sales volume of Danhong injection in public hospitals in key cities (Beijing, Guangzhou, Nanjing, Chongqing, Chengdu, Xi'an, Harbin, Shenyang, Zhengzhou) increased year by year from 2013 to 2017, and the annual growth rate fluctuated; in 2018, the sales volume of Danhong injection went down 13.11% year on year Danhong injection is only a microcosm of market adjustment of traditional Chinese medicine injection In addition to step pharmaceutical, A-share listed companies have all made statements in 2018 annual report, among which drug injection products are affected to varying degrees For example, Zhongheng group said that sales of traditional Chinese medicine injections are facing challenges due to the tightening of policies on traditional Chinese medicine injections, restrictions on the use of new medical insurance, key monitoring and other restrictions The sales of its blockbuster product Xueshuantong for injection decreased by 21.1% year on year in 2018 Longjin pharmaceutical pointed out that the main product Longjin? Breviscapine for injection failed to enter the National Essential Drug Catalogue (2018 Edition), which may be at a disadvantage in the market competition compared with similar drugs that have entered the catalogue It can be said that under the impact of policies such as limited medical insurance, key monitoring of auxiliary drugs and re evaluation after the injection goes on the market, the performance of traditional Chinese medicine injection has been affected, and the industry shuffling of auxiliary drugs is accelerating Because of the increasing clinical problems of the auxiliary drugs represented by the traditional Chinese medicine injection, the relevant departments began to step by step to establish the auxiliary drug monitoring directory On December 12, last year, the national health and Health Commission issued the notice on the management of clinical application of auxiliary drugs, which clearly defined the catalogue of auxiliary drugs at all levels (national, provincial and medical institutions), and required all provinces to report 20 varieties of the provincial catalogue before December 31, 2018, according to which the national catalogue was formulated by the national health and Health Commission The notice also clearly stipulates that all drugs in the catalogue of auxiliary drugs will be monitored The circular made further progress in February this year In February this year, a letter on Soliciting Opinions on the work of drug use monitoring and clinical comprehensive evaluation (Draft) was circulated in the industry, which was drafted by the Department of drug administration of the National Health Commission In this document, there are at least 52 varieties in the draft of national auxiliary drug catalogue, including 33 varieties of traditional Chinese medicine injection However, the promotion of any new policy will face the resistance of relevant stakeholders Although the relevant departments of the state intend to introduce policies such as clinical control and monitoring of auxiliary drugs and consistency evaluation of traditional Chinese medicine injections, as the product of decades of clinical service in China, most enterprises are living on this, including the enterprises mentioned above At present, a number of interest groups have been formed in the relevant enterprises in the country It is believed that these enterprises will also exert their influence in a series of policies restricting the use of adjuvant drugs After all, the cake of auxiliary drugs is still very attractive, so the continuous promotion of auxiliary drug monitoring policy will face more and more resistance in the future This article is reprinted by yaozhi.com The copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.